Trends in Peptides and Oligonucleotides: Choosing a Partner CDMO

Register Free: https://www.pharmtech.com/pt_w/trends

Event Overview:
Peptide and oligonucleotide drugs are versatile therapeutics with a growing range of applications and many similarities in terms and of manufacturing and regulation. New formulations often increase the complexity of the products and demand innovative solutions. Partnering with an experienced contract development and manufacturing organization can support drug developers’ manufacturing needs and allow them to focus on the core of their developments.

Key Learning Objectives:

• Changing needs during lifecycle
• Innovation and high-tech for sustainability
• Investments into capacity of peptide and oligonucleotide production

Who Should Attend:
C-level, Senior Directors, VP – Production, Research & Development, Operations

Speakers

Tycho Leifels,PhD
Group Leader Product Management
Bachem AG

Tycho Leifels,PhD, is an experienced life science portfolio professional with a successful record of leading business development and pipeline strategy. His broad expertise is based on 17 years in various commercial roles with increasing responsibilities in the life science industry, including successful international product launches and managing the portfolio towards higher profitability. He holds a PhD in chemistry from the University of Basel.

Daniel Grotzky, PhD
Head of Group Communication
Bachem AG

Daniel Grotzky, PhD, is the head of group communication at Bachem with responsibilities for internal and external communications and investor relations. Daniel joined the company in mid 2021. He has a strong track record of communications in the life science industry, with more than a decade of experience in various communications leadership roles at Roche. He holds an M.A. and PhD in political science from Ludwig-Maximilians University Munich.

Register Free: https://www.pharmtech.com/pt_w/trends